ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 381,96
0,02%
Dow Jones
42 518,62
-0,06%
DAX
19 956,88
0,24%
Brent Oil
76,295
3,30%
Bitcoin
96 866,57
2,62%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ

  6. Beam Therapeutics Inc (BEAM) Cours

Beam Therapeutics Inc

Beam Therapeutics Inc (BEAM)

NASDAQ
24,765
-0,035
( -0,14% )
Mis à jour : 17:07:17
Retardé de 15 minutes

Votre Hub pour des idées et discussions en direct en temps réel

Premium

Statistiques et détails clés

Dernier
24,765
Prix Achat
24,75
Prix Vente
24,79
Volume échangé
282 798
24,1805 Fourchette du Jour 25,015
20,84 Plage de 52 semaines 49,50
Cap du marché
2,051B
Clôture Veille
24,80
Ouverture
24,82
Dernière Transaction
100
@
24.765
Dernière heure de transaction
17:07:17
Volume financier
US$ 6 998 687
VWAP
24,748
Volume moyen (3 m)
1 164 511
Actions en circulation
82 805 627
Rendement du Dividende
-
Ratio Cours sur Bénéfices
-15,50
Bénéfice par action (BPA)
-1,6
Chiffre d'affairess
377,71M
Bénéfice net
-132,53M

À propos de Beam Therapeutics Inc

Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio co... Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. Show more

Secteur
Biological Pds,ex Diagnstics
Industrie
Biological Pds,ex Diagnstics
Site Web
www.beamtx.com
Siège social
Wilmington, Delaware, USA
Fondé
-
Beam Therapeutics Inc est coté dans le secteur Biological Pds,ex Diagnstics de la NASDAQ avec le ticker BEAM. Le dernier cours de clôture d'Beam Therapeutics était de US$24,80. Au cours de la dernière année, les actions de Beam Therapeutics ont été négociées dans une fourchette de prix de US$ 20,84 à US$ 49,50.

Beam Therapeutics compte actuellement 82 805 627 actions en circulation. La capitalisation boursière d'Beam Therapeutics est de US$2,05 milliard. Beam Therapeutics a un ratio cours/bénéfice (ratio PE) de -15.50.

BEAM Dernières nouvelles

Plus de nouvelles

Form 144 - Report of proposed sale of securities

31 Décembre 2024
Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities

31 Décembre 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

19 Décembre 2024
Edgar (US Regulatory)

Form 3 - Initial statement of beneficial ownership of securities

19 Décembre 2024
Edgar (US Regulatory)

Beam Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced...

17 Décembre 2024
GlobeNewswire Inc.

Form 8-K - Current report

09 Décembre 2024
Edgar (US Regulatory)

Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology (ASH) Annual Meeting

NHP Data Showed CD117 Monoclonal Antibody (mAb) Conditioning Successfully Achieved Long-term Engraftment of Base-edited Hematopoietic Stem Cells and Induced Robust Levels of Hemoglobin F mAb...

08 Décembre 2024
GlobeNewswire Inc.

Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting

All Seven Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to <40%, and Resolution of Anemia Post-BEAM-101 Treatment Initial Safety...

07 Décembre 2024
GlobeNewswire Inc.

Form 8-K - Current report

06 Décembre 2024
Edgar (US Regulatory)

Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer

CAMBRIDGE, Mass., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced...

06 Décembre 2024
GlobeNewswire Inc.
PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
1-3.645-12.829989440328.4129.1124.180577573626.18530441CS
4-0.815-3.1860828772525.583124.1805119343727.88213771CS
121.7157.4403470715823.0532.2921.135116451125.91818898CS
261.8658.1441048034922.934.0921.135104389126.09990825CS
52-2.185-8.1076066790426.9549.520.84120858227.45220264CS
156-54.985-68.946708463979.7582.6216.95111040736.08946655CS
2605.57529.051589369519.19138.52191394025846.00182845CS

BEAM - Frequently Asked Questions (FAQ)

What is the current Beam Therapeutics share price?
The current share price of Beam Therapeutics is US$ 24,765
How many Beam Therapeutics shares are in issue?
Beam Therapeutics has 82 805 627 shares in issue
What is the market cap of Beam Therapeutics?
The market capitalisation of Beam Therapeutics is USD 2,05B
What is the 1 year trading range for Beam Therapeutics share price?
Beam Therapeutics has traded in the range of US$ 20,84 to US$ 49,50 during the past year
What is the PE ratio of Beam Therapeutics?
The price to earnings ratio of Beam Therapeutics is -15,5
What is the cash to sales ratio of Beam Therapeutics?
The cash to sales ratio of Beam Therapeutics is 5,44
What is the reporting currency for Beam Therapeutics?
Beam Therapeutics reports financial results in USD
What is the latest annual turnover for Beam Therapeutics?
The latest annual turnover of Beam Therapeutics is USD 377,71M
What is the latest annual profit for Beam Therapeutics?
The latest annual profit of Beam Therapeutics is USD -132,53M
What is the registered address of Beam Therapeutics?
The registered address for Beam Therapeutics is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the Beam Therapeutics website address?
The website address for Beam Therapeutics is www.beamtx.com
Which industry sector does Beam Therapeutics operate in?
Beam Therapeutics operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
ONCBeiGene Ltd
 183,27
(727,40%)
22,23k
RAINRain Enhancement Technologies Holdco Inc
 5,56
(359,50%)
24,08k
NITON2OFF Inc
US$ 0,8118
(227,34%)
312,94M
CTCXCarmell Corporation
US$ 0,729
(161,20%)
204,83M
MBIOMustang Bio Inc
US$ 0,42
(137,29%)
71,8M
NMRANeumora Therapeutics Inc
US$ 2,035
(-80,80%)
21,98M
SISIShineco Inc
US$ 2,21
(-51,21%)
709,57k
BDMDBaird Medical Investment Holdings Ltd
US$ 5,1162
(-32,68%)
2,84M
SIDUSidus Space Inc
US$ 3,4884
(-28,81%)
7,41M
ARECAmerican Resources Corporation
US$ 0,7492
(-25,82%)
1,22M
NITON2OFF Inc
US$ 0,8198
(230,56%)
313,01M
CGBSCrown LNG Holdings Ltd
US$ 0,87
(117,45%)
226,97M
CTCXCarmell Corporation
US$ 0,734501
(163,17%)
204,88M
XTIAXTI Aerospace Inc
US$ 0,0414
(-3,72%)
122,29M
SVMHSRIVARU Holding Ltd
US$ 0,0477
(13,30%)
112,8M

Forums

Afficher les forums
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

NASDAQ
BEAM
Beam Therapeutics
FX
KYDBMD
KYD vs BMD
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés